Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03371329 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03371329: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03371329 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03371329, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of acute spontaneous hemorrhagic stroke.
Interventions
- BIOLOGICAL MSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2020-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03371329
The ClinicalTrials.gov registry entry for NCT03371329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSC is the first listed.
NCT03371329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03371329 about?
NCT03371329 is a clinical study titled "Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage". The overall goal of this study is to develop mesenchymal stem cell therapy for treatment of acute spontaneous hemorrhagic stroke.
What is the current status of trial NCT03371329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2017-12-12. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT03371329?
The interventions under investigation include: MSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03371329?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.